Balancing risks and therapeutic benefits. About adjuvant tamoxifen treatment for breast cancer patients

被引:7
|
作者
Sarradon-Eck, Aline [1 ]
Pellegrini, Isabelle [2 ]
机构
[1] MMSH, Ctr Norbert Elias, Equipe GReCSS PAS Anthropol Sante, F-130949 Aix En Provence, France
[2] Inst Paoli Calmette, INSERM, UMR SE4S 912, F-13273 Marseille 09, France
来源
SCIENCES SOCIALES ET SANTE | 2012年 / 30卷 / 01期
关键词
TREATMENT DECISION-MAKING; MEDICAL UNCERTAINTY; WOMENS PERCEPTIONS; CHEMOTHERAPY; HEALTH; EXPERIENCE;
D O I
10.3917/sss.301.0047
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
One of the main tools available for making bio-medical decisions about the best treatment to prescribe is the risk-benefit ratio. This article takes a contextual approach to the decision-making processes involved in the prescription of adjuvant tamoxifen as a mean of reducing the risk of relapse of breast cancer. Using anthropological descriptive methods, it examines the discrepancy between patients' and doctors' perceptions of the risks and benefits of the treatment and analyses their underlying logics. Representations of women are related to cancer (fear of the disease), its treatment (efficacy) and tamoxifen (fear of hormones and aging), and can lead to a symbolic hierarchy of treatments, whereas doctors' professional practices focus mainly on the prevention of the recurrence of cancers.
引用
收藏
页码:47 / 71
页数:25
相关论文
共 50 条
  • [41] A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer
    Dede, M.
    Gezginc, K.
    Ulubay, M.
    Alanbay, I.
    Gueran, S.
    Yenen, M.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2008, 29 (02) : 200 - 200
  • [42] Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer:: The International Breast Cancer Study Group Trial VII
    Crivellari, D
    Bonetti, M
    Castiglione-Gertsch, M
    Gelber, RD
    Rudenstam, CM
    Thürlimann, B
    Price, KN
    Coates, AS
    Hürny, C
    Bernhard, J
    Lindtner, J
    Collins, J
    Senn, HJ
    Cavalli, F
    Forbes, J
    Gudgeon, A
    Simoncini, E
    Cortes-Funes, H
    Veronesi, A
    Fey, M
    Goldhirsch, A
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) : 1412 - 1422
  • [44] TAMOXIFEN IN AXILLARY NODE-NEGATIVE BREAST-CANCER - MULTISYSTEM BENEFITS AND RISKS
    LOVE, RR
    CANCER INVESTIGATION, 1992, 10 (06) : 587 - 593
  • [45] COMBINED TAMOXIFEN AND POLYCHEMOTHERAPY IN THE ADJUVANT TREATMENT OF OPERABLE BREAST-CANCER
    STOLL, BA
    CANCER TREATMENT REPORTS, 1979, 63 (07): : 1220 - 1220
  • [46] Adjuvant tamoxifen treatment in breast cancer induces no activation of blood coagulation
    Oberhoff, C
    Winkler, UH
    Schindler, AE
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S18 - S18
  • [47] A Support Group for Breast Cancer Patients: Benefits and Risks
    Lese, Mihaela
    Lese, Ioana
    Mili, Gabriela
    REVISTA DE CERCETARE SI INTERVENTIE SOCIALA, 2014, 46 : 182 - 189
  • [48] A clinicopathologic study on patients with endometrial cancer after adjuvant tamoxifen treatment for breast cancer: A single center experience
    Ravazoula, Panagiota
    Androutsopoulos, Georgios
    Zyli, Paraskevi
    Michail, Georgios
    Kardamakis, Dimitrios M.
    Kourounis, Georgios
    BREAST JOURNAL, 2006, 12 (06): : 578 - 584
  • [49] Neo adjuvant Tamoxifen in post menopausal patients with operable breast cancer
    Salmon, RJ
    Remvikos, Y
    Campana, F
    Languille, O
    Magdalenat, H
    Asselain, B
    Clough, KB
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (10): : 831 - 834
  • [50] ULTRASONOGRAPHY SURVEILLANCE OF ENDOMETRIUM IN BREAST-CANCER PATIENTS ON ADJUVANT TAMOXIFEN
    CIATTO, S
    CECCHINI, S
    BONARDI, R
    GRAZZINI, G
    LANCET, 1994, 344 (8914): : 60 - 60